Novel technologies in cfDNA analysis and potential utility in clinic


. 2021 Dec 31;33(6):708-718.


doi: 10.21147/j.issn.1000-9604.2021.06.07.

Affiliations

Item in Clipboard

Jie Li et al.


Chin J Cancer Res.


.

Abstract

The profiling of plasma cell-free DNA (cfDNA) is becoming a valuable tool rapidly for tumor diagnosis, monitoring and prognosis. Diverse plasma cfDNA technologies have been in routine or emerging use, including analyses of mutations, copy number alterations, gene fusions and DNA methylation. Recently, new technologies in cfDNA analysis have been developed in laboratories, and potentially reflect the status of epigenetic modification, the immune microenvironment and the microbiome in tumor tissues. In this review, the authors discuss the principles, methods and effects of the current cfDNA assays and provide an overview of studies that may inform clinical applications in the near future.


Keywords:

cancer diagnosis; cfDNA; liquid biopsy; recurrence monitoring; therapy response.

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures


Figure 1



Figure 1

Diverse plasma cfDNA analysis techniques. cfDNA, cell-free DNA; TSS, transcriptional start site.


Figure 2



Figure 2

Potential clinical applications of cfDNA technologies. cfDNA, cell-free DNA; TSS, transcriptional start site.

References

    1. Malone ER, Oliva M, Sabatini PJB, et al Molecular profiling for precision cancer therapies. Genome Med. 2020;12:8. doi: 10.1186/s13073-019-0703-1.



      DOI



      PMC



      PubMed

    1. Cheng ML, Berger MF, Hyman DM, et al Clinical tumour sequencing for precision oncology: time for a universal strategy. Nat Rev Cancer. 2018;18:527–8. doi: 10.1038/s41568-018-0043-2.



      DOI



      PMC



      PubMed

    1. Murtaza M, Dawson SJ, Tsui DW, et al Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497:108–12. doi: 10.1038/nature12065.



      DOI



      PubMed

    1. Diehl F, Schmidt K, Choti MA, et al Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985–90. doi: 10.1038/nm.1789.



      DOI



      PMC



      PubMed

    1. Ulz P, Thallinger GG, Auer M, et al Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet. 2016;48:1273–8. doi: 10.1038/ng.3648.



      DOI



      PubMed

Read more here: Source link